TAR-200 Drug System Eliminates Bladder Cancer in 82% of Resistant Patients
By
geox
9mo ago· 4 min readenNews
80/100
Golden Brown
Bagelometer↗
Master baker tier. Every paragraph earns its place on the tray.
Score80TypenewsSentimentpositive
Summary
A new drug-releasing system, TAR-200, has shown remarkable success in treating high-risk non-muscle-invasive bladder cancer, eliminating tumors in 82% of patients in a phase 2 clinical trial. The miniature, pretzel-shaped device releases the chemotherapy drug gemcitabine over three weeks per cycle, proving effective for patients previously unresponsive to treatment.
Key quotes
· 3 pulledTAR-200 is a miniature, pretzel-shaped drug-device duo containing a chemotherapy drug, gemcitabine, which is inserted into the bladder through a catheter and releases the drug for three weeks per treatment cycle.
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.
In the majority of cases, the cancer disappeared after only three months of treatment, and almost half the patients...
LOS ANGELES — A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment. In the majori
